| Debug Stats | ### Total Build Time: 28 ms 36.973 KB CONCEPT_NAME gt=4 ms Completed: 4 ms rowSize= 356 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 696 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 14 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 7 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 15 bytesCONCEPT_RELATIONSHIPS gt=15 ms Completed: 15 ms rowSize= 15.672 KBCONCEPT_GENES gt=8 ms Completed: 8 ms rowSize= 19.040 KBCONCEPT_XREFS gt=1 ms Completed: 1 ms rowSize= 1.163 KBCONCEPT_ANCILLARY gt=0 Completed: 0 ms rowSize= 14 bytes- Reload Stats
|
Relationships (43)
Relation Types: diso_to_anat : 12 diso_to_diso : 29 diso_to_phen : 2
Relationships: is_abnormal_cell_of_disease : 5 is_associated_anatomic_site_of : 1 is_finding_of_disease : 4 is_normal_cell_origin_of_disease : 2 is_normal_tissue_origin_of_disease : 2 is_not_cytogenetic_abnormality_of_disease : 2 is_not_finding_of_disease : 3 is_not_molecular_abnormality_of_disease : 9 is_primary_anatomic_site_of_disease : 1 may_be_associated_disease_of_disease : 3 may_be_cytogenetic_abnormality_of_disease : 6 may_be_finding_of_disease : 4 may_be_normal_cell_origin_of_disease : 1 | |
| DISO_to_ANAT | | is_associated_anatomic_site_of |
Bone Marrow C0005953 | | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
Bone Marrow Stem Cell C1511246 | | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Cancer Cell C0334227 | | DISO_to_ANAT | | is_normal_tissue_origin_of_disease |
HEMOLYMPHORETICULAR TISSUE C1512398 | | DISO_to_ANAT | | is_normal_tissue_origin_of_disease |
Haematopoietic tissue C0229619 | | DISO_to_ANAT | | is_primary_anatomic_site_of_disease |
Hematopoietic and Lymphatic System C1512394 | | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
Hematopoietic and Lymphoid Cell C1512385 | | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Leukemic Cell C1517806 | | DISO_to_ANAT | | may_be_normal_cell_origin_of_disease |
Multipotent Bone Marrow Stem Cell C1513753 | | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic Cell C0597032 | | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic Hematopoietic and Lymphoid Cell C1513983 | | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic Myeloid Cell C1514039 | | DISO_to_DISO | | is_not_finding_of_disease |
Acute Clinical Course C1332147 | | DISO_to_DISO | | is_not_molecular_abnormality_of_disease |
BCR-ABL1 Fusion Protein Expression C1516132 | | DISO_to_DISO | | is_not_molecular_abnormality_of_disease |
BCR-FGFR1 Fusion Protein Expression C1516133 | | DISO_to_DISO | | is_not_molecular_abnormality_of_disease |
BCR-PDGFRA Fusion Protein Expression C1516135 | | DISO_to_DISO | | may_be_finding_of_disease |
Charcot-Leyden Crystals Formation C1516443 | | DISO_to_DISO | | may_be_cytogenetic_abnormality_of_disease |
Chromosome 13q deletion C2930913 | | DISO_to_DISO | | may_be_finding_of_disease |
Chronic Clinical Course C1333035 | | DISO_to_DISO | | may_be_associated_disease_of_disease |
Constrictive endocarditis C0264834 | | DISO_to_DISO | | may_be_associated_disease_of_disease |
Endomyocardial Fibrosis C0553980 | | DISO_to_DISO | | may_be_finding_of_disease |
Enlarged Liver C0019209 | | DISO_to_DISO | | may_be_finding_of_disease |
Enlarged Spleen C0038002 | | DISO_to_DISO | | is_finding_of_disease |
Eosinophil count raised (finding) C2240374 | | DISO_to_DISO | | is_not_molecular_abnormality_of_disease |
FGFR1 Gene Activation C1517090 |
|
Genes (12)
Species: human : 12 | |
| Human | FIP1L1 | 81608 | factor interacting with PAPOLA and CPSF1 | FIP1L1 and PDGFRalpha have roles in response to imatinib mesylate in chronic eosinophilic leukemia Fusion protein is detected in hypereosinophilic syndrome and chronic eosinophilic leukemia | | Human | WT1 | 7490 | Wilms tumor 1 | distinguish between idiopathic hypereosinophilic syndromes/chronic eosinophilic leukemia and reactive hypereosinophilia based on WT1 transcript amount | | Human | TCN1 | 6947 | transcobalamin I (vitamin B12 binding protein, R binder family) | Cyclic eosinophilic leukocytosis in eosinophilic leukemia with observations on transcobalamin I and eosinophils. | | Human | RNASE3 | 6037 | ribonuclease, RNase A family, 3 | The inhibitory effects of azelastine hydrochloride on PAF-induced and fMLP-induced Ca2+ influx, actin polymerization and calcium ionophore A23187-induced and aggregated IgG-induced release of eosinophil cationic protein (ECP) of an eosinophilic leukaemia cell line, EoL-1, were examined. | | Human | RASA1 | 5921 | RAS p21 protein activator (GTPase activating protein) 1 | We report a patient with a myeloproliferative disorder characterized by chronic eosinophilic leukaemia complicated by autoimmune haemolytic anaemia and a previously unreported translocation (3;5)(p13;q13), and discuss the possible contribution of the RASA gene, localized to 5q13.3, to the development of the malignant phenotype. | | Human | PDGFRA | 5156 | platelet-derived growth factor receptor, alpha polypeptide | The presence of the FIP1L1-PDGFRA fusion gene is detected in chronic eosinophilic leukemia FIP1L1 and PDGFRalpha have roles in response to imatinib mesylate in chronic eosinophilic leukemia These results indicate that the fusion of FIP1L1 to PDGFRA occurs rarely in leukemia cell lines, but they identify EOL-1 as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and for the analysis of small molecule inhibitors of FIP1L1-PDGFRalpha. | | Human | ITGB2 | 3689 | integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) | The effects of several cytokines and phorbol myristate acetate (PMA) on LFA-1 and ICAM-1 expression on a human eosinophilic leukemia cell line, EoL-3, were investigated and compared with those of a human monocytic leukemia cell line, U937. | | Human | ITGAL | 3683 | integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | The effects of several cytokines and phorbol myristate acetate (PMA) on LFA-1 and ICAM-1 expression on a human eosinophilic leukemia cell line, EoL-3, were investigated and compared with those of a human monocytic leukemia cell line, U937. Regulation of the expression of leukocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) on a human eosinophilic leukemia cell line EoL-3. | | Human | FCER2 | 2208 | Fc fragment of IgE, low affinity II, receptor for (CD23) | Eosinophils from different hypereosinophilic patients as well as the eosinophilic leukemia cell line EoL-3, analyzed by RT-PCR, expressed both CD23 a and b isoforms. The effects of interferon-alpha (IFN-alpha), INF-gamma, transforming growth factor beta (TGF-beta) and dexamethasone on low-affinity Fc receptors for IgE (Fc epsilon R2/CD23) expression on a human eosinophilic leukemia cell line, Eol-3, were examined. Differential regulation of the low affinity Fc receptor for IgE (Fc epsilon R2/CD23) and the IL-2 receptor (Tac/p55) on eosinophilic leukemia cell line (EoL-1 and EoL-3). A subclone of the EoL-3 human eosinophilic leukemia cell line (EoL-3.12) was selected for its high inducibility of CD23 (low affinity IgE receptor/Fc epsilon RII) by IL-4. | | Human | CX3CR1 | 1524 | chemokine (C-X3-C motif) receptor 1 | A human cDNA encoding a putative G protein-coupled receptor designated chemokine beta receptor-like 1 (CMKBRL1) was isolated from an eosinophilic leukemia library. | | Human | CSF2 | 1437 | colony stimulating factor 2 (granulocyte-macrophage) | Recombinant GM-CSF stimulation of either eosinophilic leukemia (EoL-1) cells or blood eosinophils in vitro results in reorganization of actin and translocation of alpha-fodrin to the plasma membrane | | Human | CD14 | 929 | CD14 molecule | Induction of eosinophilic granules, nonspecific esterase activity and CD14 expression in the human eosinophilic leukemia cell line, EOL-1. |
|